Gemini Bio-Products Breaks Ground on New Facility
Gemini Bioproducts, LLC, a leading supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm, announced that it has broken ground on a new, state-of-the-art manufacturing facility in West Sacramento. The company expect to relocate operations to the new facility during the first quarter of 2020.
The new facility will enable accelerated growth while accommodating a higher standard of quality among Gemini’s products to serve the cell and gene therapy market. The GMP facility, which spans approximately 25,000 square feet, is expected to quadruple production capacity and allow Gemini to meet its rapidly growing customer demand.
Gemini CEO Dale Gordon stated, “Our facility expansion plans are intended to support our growth by increasing capacity and allowing us to strengthen our quality systems. Through our added capabilities, we expect to be a center of excellence for cell and gene therapy companies and a trusted partner to top biopharmaceutical companies.”
Gemini offers a variety of products, including cell culture media, sera, cytokines, and growth factors. Service offerings include fill & finish and custom media development.
MarketOne Builders, a general contractor, and DGA, a science and technology architectural firm, are partnering with Gemini on the design and construction of the new facility. Gemini will be relocating from its current West Sacramento facility, which has been its headquarters since 2006.